Full Fed. Circ. Urged To Undo Hatch-Waxman Venue Limits
Valeant Pharmaceuticals on Monday urged the full Federal Circuit to review a decision that limited where Hatch-Waxman Act patent suits over generic drugs can be filed, calling it a "detrimental and...To view the full article, register now.
Already a subscriber? Click here to view full article